DE60236016D1 - Zelluläre zusammensetzungen und verfahren zur deren bereitung und verwendung - Google Patents
Zelluläre zusammensetzungen und verfahren zur deren bereitung und verwendungInfo
- Publication number
- DE60236016D1 DE60236016D1 DE60236016T DE60236016T DE60236016D1 DE 60236016 D1 DE60236016 D1 DE 60236016D1 DE 60236016 T DE60236016 T DE 60236016T DE 60236016 T DE60236016 T DE 60236016T DE 60236016 D1 DE60236016 D1 DE 60236016D1
- Authority
- DE
- Germany
- Prior art keywords
- cellular compositions
- cells
- preparation
- hematopoietic
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5073—Stem cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/36—Lipids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/12—Hepatocyte growth factor [HGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/145—Thrombopoietin [TPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/165—Vascular endothelial growth factor [VEGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/42—Notch; Delta; Jagged; Serrate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Psychiatry (AREA)
- Food Science & Technology (AREA)
- Diabetes (AREA)
- Analytical Chemistry (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34258601P | 2001-12-21 | 2001-12-21 | |
PCT/CA2002/001979 WO2003055989A2 (en) | 2001-12-21 | 2002-12-20 | Cellular compositions and methods of making and using them |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60236016D1 true DE60236016D1 (de) | 2010-05-27 |
Family
ID=23342451
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60236016T Expired - Lifetime DE60236016D1 (de) | 2001-12-21 | 2002-12-20 | Zelluläre zusammensetzungen und verfahren zur deren bereitung und verwendung |
Country Status (9)
Country | Link |
---|---|
US (3) | US7625752B2 (de) |
EP (1) | EP1458854B1 (de) |
JP (1) | JP2005512592A (de) |
AT (1) | ATE464373T1 (de) |
AU (1) | AU2002350352A1 (de) |
CA (1) | CA2470707C (de) |
DE (1) | DE60236016D1 (de) |
IL (1) | IL162648A0 (de) |
WO (1) | WO2003055989A2 (de) |
Families Citing this family (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2522890T3 (es) * | 2000-12-06 | 2014-11-19 | Anthrogenesis Corporation | Método para recolectar células troncales placentarias |
US7311905B2 (en) * | 2002-02-13 | 2007-12-25 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
US20080152629A1 (en) * | 2000-12-06 | 2008-06-26 | James Edinger | Placental stem cell populations |
KR101132545B1 (ko) * | 2001-02-14 | 2012-04-02 | 안트로제네시스 코포레이션 | 산후 포유류의 태반, 이의 용도 및 태반 줄기세포 |
US7129034B2 (en) * | 2001-10-25 | 2006-10-31 | Cedars-Sinai Medical Center | Differentiation of whole bone marrow |
AU2002350352A1 (en) * | 2001-12-21 | 2003-07-15 | Mount Sinai Hospital | Cellular compositions and methods of making and using them |
KR101042448B1 (ko) * | 2002-11-26 | 2011-06-16 | 안트로제네시스 코포레이션 | 세포요법제, 세포요법제 단위 및 이를 이용한 치료방법 |
US8790637B2 (en) | 2003-06-27 | 2014-07-29 | DePuy Synthes Products, LLC | Repair and regeneration of ocular tissue using postpartum-derived cells |
US8491883B2 (en) * | 2003-06-27 | 2013-07-23 | Advanced Technologies And Regenerative Medicine, Llc | Treatment of amyotrophic lateral sclerosis using umbilical derived cells |
US9572840B2 (en) | 2003-06-27 | 2017-02-21 | DePuy Synthes Products, Inc. | Regeneration and repair of neural tissue using postpartum-derived cells |
US8518390B2 (en) | 2003-06-27 | 2013-08-27 | Advanced Technologies And Regenerative Medicine, Llc | Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells |
PL1641916T3 (pl) | 2003-06-27 | 2016-08-31 | Depuy Synthes Products Inc | Regeneracja i naprawa tkanki nerwowej z wykorzystaniem komórek poporodowych |
US7875272B2 (en) * | 2003-06-27 | 2011-01-25 | Ethicon, Incorporated | Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells |
US9592258B2 (en) | 2003-06-27 | 2017-03-14 | DePuy Synthes Products, Inc. | Treatment of neurological injury by administration of human umbilical cord tissue-derived cells |
GB0329449D0 (en) * | 2003-12-19 | 2004-01-28 | Omnicyte Ltd | Stem cells |
WO2005073366A1 (en) | 2004-01-30 | 2005-08-11 | Lifecord Inc. | Method for isolating and culturing multipotent progenitor/stem cells from umbilical cord blood and method for inducing differentiation thereof |
EP1735429A4 (de) * | 2004-03-31 | 2008-06-11 | Newlink Genetics Corp | Verfahren und zusammensetzungen zur gewinnung von embryonalen stammzellen abstammender hämatopoetischer stammzellen und verwendungen davon |
US7622108B2 (en) * | 2004-04-23 | 2009-11-24 | Bioe, Inc. | Multi-lineage progenitor cells |
CA2563518C (en) * | 2004-04-23 | 2014-09-02 | Bioe, Inc. | Multi-lineage progenitor cells |
ATE521699T1 (de) * | 2004-12-14 | 2011-09-15 | Kwalata Trading Ltd | Herstellung von neurallinienzellen aus blut |
WO2006101548A2 (en) * | 2004-12-21 | 2006-09-28 | Ethicon, Inc. | Postpartum cells derived from umbilical cord tissue, and methods of making, culturing, and using the same |
US20060153815A1 (en) * | 2004-12-21 | 2006-07-13 | Agnieszka Seyda | Tissue engineering devices for the repair and regeneration of tissue |
US20060166361A1 (en) * | 2004-12-21 | 2006-07-27 | Agnieszka Seyda | Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same |
CA2589041C (en) | 2004-12-23 | 2019-08-20 | Ethicon, Incorporated | Postpartum cells derived from umbilical cord tissue, and methods of making and using the same |
EP1835924B1 (de) | 2004-12-23 | 2013-08-21 | Ethicon, Incorporated | Behandlung von morbus parkinson und verwandter erkrankungen mit post partum erhaltenen zellen |
WO2008048671A1 (en) * | 2006-10-18 | 2008-04-24 | University Of Illinois | Embryonic-like stem cells derived from adult human peripheral blood and methods of use |
US9388382B2 (en) | 2005-10-05 | 2016-07-12 | The Board Of Trustees Of The University Of Illinois | Isolation of CD14 negative, CD45 positive and CD117 positive embryonic-like stem cells free of monocytes from human umbilical cord blood mononuclear cells |
EP2530146A1 (de) | 2005-10-13 | 2012-12-05 | Anthrogenesis Corporation | Immunmodulation unter Verwendung von Plazenta-Stammzellen |
CN101864392B (zh) * | 2005-12-13 | 2016-03-23 | 国立大学法人京都大学 | 核重新编程因子 |
US9175261B2 (en) * | 2005-12-16 | 2015-11-03 | DePuy Synthes Products, Inc. | Human umbilical cord tissue cells for inhibiting adverse immune response in histocompatibility-mismatched transplantation |
EP1976975B1 (de) * | 2005-12-19 | 2012-08-01 | Ethicon, Inc. | In-vitro-expansion von postpartum gewonnenen zellen in rollerflaschen |
SG170789A1 (en) * | 2005-12-28 | 2011-05-30 | Ethicon Inc | Treatment of peripheral vascular disease using postpartum-derived cells |
US9125906B2 (en) | 2005-12-28 | 2015-09-08 | DePuy Synthes Products, Inc. | Treatment of peripheral vascular disease using umbilical cord tissue-derived cells |
AU2006332679A1 (en) * | 2005-12-29 | 2007-07-12 | Anthrogenesis Corporation | Co-culture of placental stem cells and stem cells from a second source |
CN103060263B (zh) | 2005-12-29 | 2016-03-16 | 人类起源公司 | 胎盘干细胞群 |
TW200734462A (en) | 2006-03-08 | 2007-09-16 | In Motion Invest Ltd | Regulating stem cells |
CN102626517B (zh) * | 2006-03-24 | 2015-07-29 | 儿童医疗中心有限公司 | 调节造血干细胞生长的方法 |
US7727763B2 (en) * | 2006-04-17 | 2010-06-01 | Bioe, Llc | Differentiation of multi-lineage progenitor cells to respiratory epithelial cells |
EP2679221B1 (de) | 2006-10-20 | 2020-09-23 | Children's Medical Center Corporation | Verfahren zur Verbesserung der Geweberegeneration |
NZ606814A (en) * | 2006-10-23 | 2014-10-31 | Anthrogenesis Corp | Methods and compositions for treatment of bone defects with placental cell populations |
KR101569168B1 (ko) | 2007-02-12 | 2015-11-13 | 안트로제네시스 코포레이션 | 태반 줄기세포를 이용한 염증 질환의 치료 |
US20100143476A1 (en) * | 2007-02-14 | 2010-06-10 | March Keith L | Composition for stimulating formation of vascular structures |
WO2008104065A1 (en) * | 2007-02-26 | 2008-09-04 | Mount Sinai Hospital | Neural cell preparations and methods of making and using them |
CA2679178A1 (en) * | 2007-02-26 | 2008-09-04 | Mount Sinai Hospital | Compositions and methods for treating peripheral vascular diseases |
EP2137297A4 (de) * | 2007-04-11 | 2010-04-14 | Roger Deutsch | Verfahhren zur diagnostizierung biologischer proben mit stammzellen |
US9404084B2 (en) | 2007-06-20 | 2016-08-02 | Kwalata Trading Limited | Regulating stem cells |
US20080318314A1 (en) * | 2007-06-20 | 2008-12-25 | Valentin Fulga | Production from blood of cells of neural lineage |
CN101835479A (zh) * | 2007-07-25 | 2010-09-15 | 佰欧益有限公司 | 多系祖细胞分化为软骨细胞 |
WO2009046335A1 (en) * | 2007-10-05 | 2009-04-09 | Ethicon, Incorporated | Repair and regeneration of renal tissue using human umbilical cord tissue-derived cells |
US8236538B2 (en) | 2007-12-20 | 2012-08-07 | Advanced Technologies And Regenerative Medicine, Llc | Methods for sterilizing materials containing biologically active agents |
WO2009117553A2 (en) * | 2008-03-20 | 2009-09-24 | University Of Florida Research Foundation, Inc. | Enhancing vessel lesion homing and repair potential of stem cells |
US20090291494A1 (en) * | 2008-05-21 | 2009-11-26 | Bioe, Inc. | Differentiation of Multi-Lineage Progenitor Cells to Pancreatic Cells |
WO2009155041A2 (en) * | 2008-05-28 | 2009-12-23 | Children's Medical Center Corporation | Method to modulate hematopoietic stem cell growth |
EP2331109B1 (de) | 2008-08-22 | 2013-05-29 | Anthrogenesis Corporation | Verfahren und zusammensetzungen zur behandlung von knochendefekten mit plazenta-zellpopulationen |
GB0818725D0 (en) | 2008-10-13 | 2008-11-19 | Habib Nagy A | Pharmaceutical composition |
WO2010071863A1 (en) * | 2008-12-19 | 2010-06-24 | Ethicon, Incorporated | Regeneration and repair of neural tissue following injury |
US10179900B2 (en) * | 2008-12-19 | 2019-01-15 | DePuy Synthes Products, Inc. | Conditioned media and methods of making a conditioned media |
CN102481321B (zh) * | 2008-12-19 | 2017-12-19 | 德普伊新特斯产品公司 | 用于治疗神经病性疼痛和痉挛状态的脐带组织来源的细胞 |
PL2379088T3 (pl) | 2008-12-19 | 2018-07-31 | DePuy Synthes Products, Inc. | Leczenie płuca oraz chorób i zaburzeń płucnych |
US9051548B2 (en) | 2009-02-03 | 2015-06-09 | Children's Medical Center Corporation | Methods for enhancing hematopoietic stem/progenitor cell engraftment |
US9056085B2 (en) | 2009-02-03 | 2015-06-16 | Children's Medical Center Corporation | Methods for enhancing hematopoietic stem/progenitor cell engraftment |
CA2753679C (en) * | 2009-02-27 | 2021-03-02 | Cellular Dynamics International, Inc. | Differentiation of pluripotent cells |
CN102498204B (zh) * | 2009-03-26 | 2015-02-04 | 德普伊新特斯产品有限责任公司 | 人脐带组织细胞作为用于阿尔茨海默病的疗法 |
KR20130092394A (ko) | 2010-04-08 | 2013-08-20 | 안트로제네시스 코포레이션 | 태반 줄기 세포를 사용한 사르코이드증의 치료 |
WO2011143411A1 (en) * | 2010-05-12 | 2011-11-17 | Abt Holding Company | Modulation of splenocytes in cell therapy for traumatic brain injury |
SG10201913920PA (en) | 2010-05-12 | 2020-03-30 | Abt Holding Co | Modulation of splenocytes in cell therapy |
WO2012046065A2 (en) * | 2010-10-06 | 2012-04-12 | Omnicyte Limited | Culture method |
EP2625577B1 (de) | 2010-10-08 | 2019-06-26 | Terumo BCT, Inc. | Anpassbares verfahren und systeme für züchtung und ernte von zellen in einem hohlfaser-bioreaktorsystem |
US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
US9783601B2 (en) | 2010-12-01 | 2017-10-10 | Alderbio Holdings Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
EP2658557A1 (de) | 2010-12-31 | 2013-11-06 | Anthrogenesis Corporation | Verbesserung der plazentastammzellenpotenz mit modulatorischen rna-molekülen |
US20130331326A1 (en) * | 2011-02-21 | 2013-12-12 | Duke University | Method of inducing hematopoietic reconstruction |
AU2012262273B2 (en) | 2011-06-01 | 2017-09-14 | Celularity Inc. | Treatment of pain using placental stem cells |
WO2013055476A1 (en) | 2011-09-09 | 2013-04-18 | Anthrogenesis Corporation | Treatment of amyotrophic lateral sclerosis using placental stem cells |
EP2785350B1 (de) | 2011-12-02 | 2018-05-02 | Fate Therapeutics, Inc. | Verbesserte verfahren zur behandlung von ischämie |
JP6220791B2 (ja) | 2011-12-02 | 2017-10-25 | フェイト セラピューティクス,インコーポレイテッド | 増強された幹細胞組成物 |
WO2013096686A1 (en) | 2011-12-23 | 2013-06-27 | Advanced Technologies And Regenerative Medicine, Llc | Detection of human umbilical cord tissue-derived cells |
US9943545B2 (en) | 2013-03-15 | 2018-04-17 | Fate Therapeutics, Inc. | Stem cell culture media and methods of enhancing cell survival |
US10851412B2 (en) | 2013-03-15 | 2020-12-01 | Fate Therapeutics, Inc. | Cell potency assay for therapeutic potential |
EP2796545A1 (de) * | 2013-04-26 | 2014-10-29 | Université Pierre et Marie Curie (Paris 6) | Verfahren zur Herstellung von Retinavorläufern, pigmentierten Retinaepithelzellen und neuronalen Retinazellen |
WO2015073751A1 (en) * | 2013-11-15 | 2015-05-21 | Applied Stemcell, Inc. | Methods for isolating lineage-specific cells |
US9617506B2 (en) | 2013-11-16 | 2017-04-11 | Terumo Bct, Inc. | Expanding cells in a bioreactor |
EP3074505B1 (de) * | 2014-02-14 | 2018-06-06 | National University of Ireland Galway | Serumfreies medium |
CN106232800B (zh) | 2014-03-25 | 2020-07-03 | 泰尔茂比司特公司 | 介质的被动替代 |
JP6830059B2 (ja) | 2014-09-26 | 2021-02-17 | テルモ ビーシーティー、インコーポレーテッド | スケジュール化された細胞フィーディング |
WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
EP3464565A4 (de) | 2016-05-25 | 2020-01-01 | Terumo BCT, Inc. | Zellexpansion |
US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
EP3656841A1 (de) | 2017-03-31 | 2020-05-27 | Terumo BCT, Inc. | Zellexpansion |
US20200270576A1 (en) * | 2017-09-14 | 2020-08-27 | The Regents Of The University Of California | Ex Vivo Maintenance and Expansion of Stem Cells |
WO2022204315A1 (en) | 2021-03-23 | 2022-09-29 | Terumo Bct, Inc. | Cell capture and expansion |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5091206A (en) * | 1987-10-26 | 1992-02-25 | Baxter Diagnostics Inc. | Process for producing magnetically responsive polymer particles and application thereof |
US5665557A (en) * | 1994-11-14 | 1997-09-09 | Systemix, Inc. | Method of purifying a population of cells enriched for hematopoietic stem cells populations of cells obtained thereby and methods of use thereof |
US5677136A (en) * | 1994-11-14 | 1997-10-14 | Systemix, Inc. | Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof |
US5728581A (en) * | 1995-06-07 | 1998-03-17 | Systemix, Inc. | Method of expanding hematopoietic stem cells, reagents and bioreactors for use therein |
AU5083098A (en) | 1996-10-25 | 1998-05-22 | Icogen Corporation | Use of leptin to stimulate hematopoiesis |
US20020155108A1 (en) * | 1998-05-04 | 2002-10-24 | Biocrystal, Ltd. | Method for ex vivo loading of antigen presenting cells with antigen, and a vaccine comprising the loaded cells |
ATE368731T1 (de) | 1998-05-29 | 2007-08-15 | Osiris Therapeutics Inc | Menschliche cd45+ und/oder fibroblasten+ mesenchymale stammzellen |
WO2000017326A1 (en) * | 1998-09-21 | 2000-03-30 | Musc Foundation For Research Development | Non-hematopoietic cells, including cardiomyocytes and skeletal muscle cells, derived from hematopoietic stem cells and methods of making and using them |
EP1218487A2 (de) | 1999-09-23 | 2002-07-03 | Cell Science Therapeutics | Verfahren und vorrichtungen zur herstellung von nicht hematopoietischen zellenlinien aus hematopoietischen vorläuferzellen |
IL151650A0 (en) * | 2000-03-09 | 2003-04-10 | Saneron Ccel Therapeutics Inc | Human cord blood as a source of neural tissue for repair of the brain and spinal cord |
WO2001071016A1 (en) * | 2000-03-23 | 2001-09-27 | Stemcells, Inc. | Pluripotential stem cells |
JPWO2003038077A1 (ja) * | 2001-10-30 | 2005-02-24 | 第一製薬株式会社 | 造血幹細胞の増幅方法 |
AU2002350352A1 (en) * | 2001-12-21 | 2003-07-15 | Mount Sinai Hospital | Cellular compositions and methods of making and using them |
EP1735429A4 (de) * | 2004-03-31 | 2008-06-11 | Newlink Genetics Corp | Verfahren und zusammensetzungen zur gewinnung von embryonalen stammzellen abstammender hämatopoetischer stammzellen und verwendungen davon |
CA2679178A1 (en) * | 2007-02-26 | 2008-09-04 | Mount Sinai Hospital | Compositions and methods for treating peripheral vascular diseases |
-
2002
- 2002-12-20 AU AU2002350352A patent/AU2002350352A1/en not_active Abandoned
- 2002-12-20 CA CA2470707A patent/CA2470707C/en not_active Expired - Fee Related
- 2002-12-20 IL IL16264802A patent/IL162648A0/xx unknown
- 2002-12-20 EP EP02784995A patent/EP1458854B1/de not_active Expired - Lifetime
- 2002-12-20 AT AT02784995T patent/ATE464373T1/de not_active IP Right Cessation
- 2002-12-20 JP JP2003556509A patent/JP2005512592A/ja active Pending
- 2002-12-20 US US10/499,849 patent/US7625752B2/en not_active Expired - Fee Related
- 2002-12-20 DE DE60236016T patent/DE60236016D1/de not_active Expired - Lifetime
- 2002-12-20 WO PCT/CA2002/001979 patent/WO2003055989A2/en active Application Filing
-
2009
- 2009-11-06 US US12/613,821 patent/US20100104543A1/en not_active Abandoned
-
2012
- 2012-10-12 US US13/650,596 patent/US20130064801A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ATE464373T1 (de) | 2010-04-15 |
US20050074435A1 (en) | 2005-04-07 |
US7625752B2 (en) | 2009-12-01 |
CA2470707A1 (en) | 2003-07-10 |
US20100104543A1 (en) | 2010-04-29 |
IL162648A0 (en) | 2005-11-20 |
AU2002350352A1 (en) | 2003-07-15 |
WO2003055989A3 (en) | 2003-10-30 |
US20130064801A1 (en) | 2013-03-14 |
WO2003055989A2 (en) | 2003-07-10 |
CA2470707C (en) | 2014-07-08 |
JP2005512592A (ja) | 2005-05-12 |
EP1458854A2 (de) | 2004-09-22 |
EP1458854B1 (de) | 2010-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE464373T1 (de) | Zelluläre zusammensetzungen und verfahren zur deren bereitung und verwendung | |
BR0114475A (pt) | Célula para a produção de composição de anticorpo | |
WO2006105152A3 (en) | Amnion-derived cell compositions, methods of making and uses thereof | |
HUP0303428A2 (hu) | Expressziós eljárás hibrid izotípusú antitestcsoportot tartalmazó fehérjékhez | |
SG149061A1 (en) | Definitive endoderm | |
WO2004046312A3 (en) | Methods for in vitro expansion of hematopoietic stem cells | |
GB2392674A (en) | Mesenchymal cells and osteoblasts from human embryonic stem cell | |
WO2004087896A3 (en) | Hepatocyte differentiation of stem cells | |
EA200401591A1 (ru) | Керамические аноды и способ их изготовления | |
BR0318087A (pt) | Método para produzir partìculas cerâmicas | |
DE60230858D1 (de) | Chemisch definiertes medium für kultivierte säugerzellen | |
ATE405644T1 (de) | Verfahren zur herstellung und reinigung von erythropoietin | |
DE60232234D1 (de) | Verfahren zur kultivierung von circovirus | |
ATE371631T1 (de) | Glasszusammensetzung zur herstellung ultrafeiner fasern | |
UA81398C2 (en) | Keratinocytes which may be used as biologically active substances for the treatment of wounds | |
ATE482966T1 (de) | Verfahren zur herstellung von 7-alpha-alkylierte 19-norsteroide | |
DE69939312D1 (de) | Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen | |
DE50106328D1 (de) | Verfahren zur herstellung bioaktiver implantatoberflächen | |
IL196900A0 (en) | Autologous t-cell vaccines compositions | |
DE60106469D1 (de) | Verfahren zur Herstellung von genetisch veränderten Lymphozyten Vorläuferzellen von Wirbeltieren und deren Gebrauch zur Produktion von heterologen Bindeproteinen | |
DE59913565D1 (de) | Rekombinanter stabiler zellklon, seine herstellung und verwendung | |
HK1063334A1 (en) | Compositions and methods useful for hcv infection | |
ATE397058T1 (de) | In vitro rekonstituierte lagen des menschlichen hornhautepithels und verfahren zur herstellung davon | |
ATE443756T1 (de) | Chondroitin synthasegen und verfahren zur dessen herstellung und anwendung | |
MXPA03007413A (es) | Composicion y metodo para tratar enfermedades inflamatorias. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |